The FDA approved a once-weekly, long-acting basal insulin for adults with type 2 diabetes as an alternative to daily basal ...

SUPER-1 evaluated GZR4 in insulin-naïve Chinese adults with T2DM, while SUPER-2 assessed those previously treated with basal insulin.

CNW/ -- (SSE: 603087) today announced that two pivotal phase 3 clinical trials, SUPER-1 and SUPER-2, evaluating ...

The FDA’s decision is based on data from the ONWARDS Phase IIIa clinical programme involving nearly 2,680 adults.

Researchers in Japan have reported a significant step in the long‑standing scientific effort to develop an insulin medication ...

Most types of insulin therapy, an important part of diabetes treatment for many people, are given as daily injections to help manage blood sugar levels. Now, the maker of a once-weekly insulin ...

Unlike injectable diabetes drugs such as Ozempic and Mounjaro, which help lower blood sugar by mimicking hormones that ...

MADRID — The de-escalation of a multiple daily injection regimen of insulin for type 2 diabetes to a once-daily fixed-ratio combination of insulin glargine U100 and glucagon-like peptide 1 receptor ...

Adults with type 1 diabetes had an increase in total daily insulin dose and bolus insulin dose shortly after stopping ...

Most diabetes patients must carefully monitor their blood sugar levels and inject insulin multiple times per day, to help ...

Share on Pinterest The FDA has approved islet cellular therapy for type 1 diabetes for the first time. Image credit: Catherine Falls Commercial/Getty Images In 2021, about 8.4 million people globally ...